3-{[1-(tert-butoxycarbonyl)piperidin-4-yl]methyl}-2-phenylquinoline-4-carboxylic acid | 914654-64-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 3-{[1-(tert-butoxycarbonyl)piperidin-4-yl]methyl}-2-phenylquinoline-4-carboxylic acid
• 英文别名: 3-{1-[(1,1-dimethylethoxy)carbonyl]piperidin-4-yl}methyl-2-phenylquinoline-4-carboxylic acid；{1-[(1,1-Dimethylethoxy)carbonyl]piperidin-4-yl}methyl-2-phenylquinoline-4-carboxylic Acid；3-[[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-4-yl]methyl]-2-phenylquinoline-4-carboxylic acid
• CAS: 914654-64-1
• 化学式: C₂₇H₃₀N₂O₄
• 分子量: 446.546
• InChiKey: IYSKJXWSPADGIT-UHFFFAOYSA-N

物化性质

• 沸点：
  606.0±55.0 °C(Predicted)
• 密度：
  1.212±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  33
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  79.7
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-{[1-(tert-butoxycarbonyl)piperidin-4-yl]methyl}-2-phenylquinoline-4-carboxylic acid 在 草酰氯 、 potassium carbonate 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 、 水 、 甲苯 为溶剂， 生成 Methyl 2-{[3-({1-[(1,1-Dimethylethoxy)carbonyl]piperidin-4-yl}methyl)-2-phenylquinolin-4-yl]carbonyl}-1-phenylhydrazinecarboxylate
  参考文献：
  名称：

  N′,2-Diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists II

  摘要：

  Introduction of selected amine containing side chains into the 3-position of N',2-diphenylquinoline-4-carbohydrazide based NK3 antagonists abolishes unwanted hPXR activation. Introduction of a fluorine at the 8-position is necessary to minimize unwanted hIK(r) affinity and a piperazine N-tert-butyl group is necessary for metabolic stability. The lead compound (8m) occupies receptors within the CNS following oral dosing (Occ(90) 7 mg/kg po; plasma Occgo 0.4 mu M) and has good selectivity and excellent PK properties. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.08.085
• 作为产物：
  描述：

  N-Boc-4-哌啶甲醇 在 palladium on activated charcoal 氢氧化钾 、 草酰氯 、 氢气 、 二甲基亚砜 、 甲基磺酰氯 、 三乙胺 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 水 、 乙酸乙酯 为溶剂， 生成 3-{[1-(tert-butoxycarbonyl)piperidin-4-yl]methyl}-2-phenylquinoline-4-carboxylic acid
  参考文献：
  名称：

  N′,2-Diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists II

  摘要：

  Introduction of selected amine containing side chains into the 3-position of N',2-diphenylquinoline-4-carbohydrazide based NK3 antagonists abolishes unwanted hPXR activation. Introduction of a fluorine at the 8-position is necessary to minimize unwanted hIK(r) affinity and a piperazine N-tert-butyl group is necessary for metabolic stability. The lead compound (8m) occupies receptors within the CNS following oral dosing (Occ(90) 7 mg/kg po; plasma Occgo 0.4 mu M) and has good selectivity and excellent PK properties. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.08.085

文献信息

• Quinoline derivatives as neurokinin receptor antagonists
  申请人：Carling William Robert

  公开号：US20090054440A1

  公开（公告）日：2009-02-26

  The present invention relates to substituted quinoline hydrazides of Formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 , X, Y and Z are defined herein, pharmaceutical compositions comprising them and their use in treating diseases mediated by neurokinin-2 and/or neurokinin-3 (NK-3) receptors. These compounds can thus be used in methods of treatment to suppress and treat such disorders.

  本发明涉及式(I)所示的取代喹啉酰肼：其中R1、R2、R3、R4、R5、X、Y和Z在此定义，包含它们的药物组合物及其在治疗由神经激肽-2和/或神经激肽-3 (NK-3)受体介导的疾病中的用途。因此，这些化合物可用于治疗方法，以抑制和治疗这些疾病。
• Quinoline Derivatives as Neurokinin Receptor Antagonists
  申请人：Crawforth James Michael

  公开号：US20090143429A1

  公开（公告）日：2009-06-04

  The present invention relates to substituted quinoline derivatives of Formula (I); wherein hal, n, A, formula (a), R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are defined herein, pharmaceutical compositions comprising them and their use in treating diseases mediated by neurokinin-2 and/or neurokinin-3 (NK-3) receptors. These compounds can thus be used in methods of treatment to suppress and treat such disorders.

  本发明涉及公式(I)的取代喹啉衍生物；其中hal、n、A、公式(a)、R1、R2、R3、R4、R5和R6在此定义，包括它们的制药组合物以及它们在治疗通过神经激肽-2和/或神经激肽-3（NK-3）受体介导的疾病中的应用。这些化合物可用于治疗和抑制这些疾病的方法。